Human pluripotent stem cells (hPSCs) offer the opportunity to generate neuronal cells, including nociceptors. Using a chemical-based approach, we generated nociceptive sensory neurons from HUES6 embryonic stem cells and retrovirally reprogrammed induced hPSCs derived from fibroblasts. The nociceptive neurons expressed respective markers and showed tetrodotoxin-sensitive (TTXs) and -resistant (TTXr) voltage-gated sodium currents in patch-clamp experiments. In contrast to their counterparts from rodent dorsal root ganglia, TTXr currents of hPSC-derived nociceptors unexpectedly displayed a significantly more hyperpolarized voltage dependence of activation and fast inactivation. This apparent discrepancy is most likely due to a substantial expression of the developmentally important sodium channel NAV1.5. In view of the obstacles to recapitulate neuropathic pain in animal models, our data advance hPSC-derived nociceptors as a better model to study developmental and pathogenetic processes in human nociceptive neurons and to develop more specific small molecules to attenuate pain.
INTRODUCTION
Human pluripotent stem cells (hPSCs), i.e., human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs), can give rise to functional neurons (reviewed in Gage and Temple, 2013) . Human peripheral neurons are difficult to differentiate, but a recently published combinatorial small molecule-based approach was able to overcome this shortage (Chambers et al., 2012) . These neurons express canonical markers of nociceptors, such as TAC1 (pro-peptide to Substance P), SCN9A (NAV1.7), and SCN10A (NAV1.8). They exhibit currents mediated by ASIC, GABA A receptors, HCN1, and KCNQ2/3 (Young et al., 2014) .
Neuropathic pain is a disabling and difficult to treat condition that cannot be adequately mimicked in animal models. Recently, inherited neuropathic pain syndromes were linked to mutations in voltage-gated sodium channels (NAVs) (Lampert et al., 2014) , stressing the importance of TTXr NAVs in neuropathic pain and as targets for novel, specific pain treatment (Bagal et al., 2014) .
Nociceptive stimuli are conveyed by NAVs that comprise nine different subtypes expressed in human and rodents. Six are tetrodotoxin-sensitive (TTXs) (NAV1.1 to NAV1.4, NAV1.6, and NAV1.7), whereas three are resistant to TTX (TTXr) (NAV1.5, NAV1.8, and NAV1.9). Inherited small fiber neuropathies (SFN) are, among others, associated with mutations in NAV1.8 (Faber et al., 2012) . NAVs undergo expression changes during development, and pain syndromes linked to NAV mutations occur at certain periods in life; while the NAV1.7-linked severe pain syndrome PEPD (paroxysmal extreme pain disorder) can start in utero, with symptoms declining during adulthood, the NAV1.7-linked erythromelalgia has its onset in adolescence, and SFN is observed in older adults (Lampert et al., 2014) . This striking variation in disease onset may be due to modulation of the mutation phenotypes by co-expression of different NAV subtypes, but experimental support for this hypothesis is still missing. Expression and function of NAVs depend critically on the cellular background (Rush et al., 2006) , sounding a strong note of caution when translating data from rodent to human. This holds particularly true for nociceptors whose excitability is controlled by a complex interplay between TTXs and TTXr NAVs. Thus, there is an urgent need for the availability of human nociceptors to investigate the pathophysiology and pharmacology of nociception in an appropriate model.
Even though hPSC-derived nociceptors are a promising cellular model in pain research, a detailed investigation of their set of NAV subtypes is still missing. Using hPSCderived nociceptors, generated by applying an optimized protocol (Chambers et al., 2012) , we explored the maturational stages of hPSC-derived nociceptors and deciphered the electrophysiological characteristics of their TTXr NAVs. Our analysis revealed that the generated neurons not only express NAV1.8 and NAV1.9, but also the developmentally regulated NAV1.5, suggesting that the derived neurons represent a specific stage during development.
RESULTS AND DISCUSSION

hPSC-Derived Sensory Neurons Express Key Nociceptor Markers
Using an optimized protocol for small molecule inhibition ( Figure 1A ), gained by adapting growth factor concentrations, antioxidant supplementation, and optimized cell seeding densities of a previously published protocol (Chambers et al., 2012) , we successfully differentiated hESCs (HUES6 line) and hiPSCs (previously published as control lines iPSC Ctrl-11 and Ctrl-12) (Havlicek et al., 2014) into human sensory neurons. The reproducibility of the relative amount of nociceptors and reduced intraline variation were obtained when adjusting cell seeding densities to 85,000-100,000 cells/cm 2 (compared with 20,000-40,000 cells/cm 2 in Chambers et al., 2012) , lowering the neurotrophic factor concentrations to 20 ng/ml, and supplementing the medium with the antioxidant ascorbic acid. The generated neurons grow in ganglion-like clusters ( Figure 1B ) comparable to those of other mammalian sensory neurons (e.g., rat dorsal root ganglion neurons [DRGs] ). Immunofluorescence stainings indicated the expression of canonical peripheral markers, such as BRN3A, PERIPHERIN, and TUJ1 ( Figures 1C and 1D ). The expression of the nociceptor-specific capsaicin receptor TRPV1 ( Figure 1E ) revealed that the majority of TUJ1-positive cells harbored nociceptor identity (83% of TUJ1-positive cells within ganglion-like clusters were TRPV1 positive). Compared with undifferentiated hiPSCs, the pan-neuronal NAVs NAV1.1, NAV1.2 and NAV1.6 (corresponding to genes SCN1A, SCN2A, and SCN8A) were upregulated in nociceptors ( Figure 1F ), indicating the successful differentiation into neuronal cells (Catterall et al., 2005) . The expression of genes specific for peripheral sensory neurons such as NAV1.7 (SCN9A), the P 2 X 3 receptor (P2RX3), and TRPV1 were upregulated in the differentiated nociceptors compared with hiPSCs ( Figure 1G ).
For performing a functional analysis, we tested neuronal excitability by whole-cell patch-clamp experiments. When electrically evoked, hPSC-derived nociceptors fired tonically (9 of 29) or phasically (15 of 29) as described for rodent sensory neurons ( Figure 1H ; e.g., Freisinger et al., 2013) , and only few cells were not electrically active (5 of 29). Consecutive voltage clamp recordings of each cell revealed the characteristic ionic signature of neuronal excitability, with brief NAV-mediated inward currents followed by sustained outward currents ( Figure 1I ). TTX (500 nM) was used to delineate TTXr NAVs in hPSC-derived nociceptors, for which a sample recording is shown in Figure 1J .
TTXr Currents in hPSC-Derived Nociceptors
Of the three known TTXr NAVs, NAV1.8 and NAV1.9 are expressed in the peripheral nervous system, and NAV1.5 is mainly present in the heart (Catterall, 2012) . However, NAV1.5 is also found in rat DRGs during development (Renganathan et al., 2002) . We therefore compared expression levels of NAV1.5, NAV1.8, and NAV1.9 in hPSC-derived nociceptors ( Figure 2A ). Undifferentiated hiPSCs already showed substantial expression of SCN5A, suggesting that this channel may play a role during early human development. Upon differentiation of hiPSCs into nociceptors, SCN5A remained present, indicating its importance for sensory neuron development. We found a substantial increase in SCN10A (encoding NAV1.8) and SCN11A, encoding the slowly gating NAV1.9, confirming that the differentiated cells acquired a peripheral neuron identity. The abundance of NAV1.5 and NAV1.9 protein was confirmed by immunofluorescence stainings ( Figure 2B ). We evaluated several NAV1.8 antibodies; however, all failed to be specific in heterologous expression systems (data not shown).
We explored whether TTXr NAVs of hPSC-derived nociceptors display the distinct biophysical characteristics. In whole-cell recordings performed in the presence of 500 nM TTX, 79% of cells displayed substantial fast TTXr NAV currents with properties similar to those of human NAV1.8 when heterologously expressed in the neuroblastoma cell line ND7/23 ( Figure 2C ). We focused on fastgating NAVs, as currents resembling NAV1.9 were only weakly expressed (data not shown). Compared with heterologously expressed NAV1.8, voltage dependence of activation was much more hyperpolarized in human nociceptors ( Figure 2D ), suggesting that either NAV1.8 displays different gating properties in human nociceptors or that other NAVs were also involved. In support of the latter, the voltage dependence of activation of hPSC-derived nociceptors was indeed more similar to that of heterologously (legend continued on next page) expressed NAV1.5 than to that of NAV1.8 ( Figure 2D ; Table S1 ).
We focused on fast-inactivation properties, as these are very distinct between NAV1.5 and NAV1.8 in heterologous expression systems. As demonstrated in Figure 2E , the voltage dependence of steady-state fast inactivation of hPSC-derived nociceptors was hyperpolarized compared with NAV1.8, and rather in the range of that of NAV1.5.
Nevertheless, V half of fast inactivation of TTXr currents from hPSC-derived nociceptors was more hyperpolarized than that of NAV1.5 alone in heterologous systems (Table S1 ). This may be due to either the expression of NAV1.9, or to the cellular background, which was shown to differentially affect gating of human NAVs (e.g., Rush et al., 2006) .
hPSC-Derived Nociceptors Exhibit an Embryonic-like Expression Pattern of TTXr NAVs
Our results show that hPSC-derived nociceptors express an electrophysiologically relevant level of functional NAV1.5. Rat DRGs are well studied and available for comparison of the expression patterns of TTXr NAVs during development. Thus, we performed qRT-PCR experiments on E14-E16 and P6 rat DRGs. Scn5a was strongly expressed at E14-E16, but its expression levels declined after birth as expected (Figure 3A) (Renganathan et al., 2002) . mRNA levels of Scn9a and Scn10a did not change significantly, whereas Scn11a was strongly upregulated after birth ( Figure 3A ). Wholecell recordings showed fast-activating and -inactivating currents in DRGs from both E14-E16 and P6 rats, although current density was significantly lower in E14-E16 cells (E14-E16 cells: 104.4 ± 29.4 pF, n = 4; P6 cells: 196.2 ± 39.8 pA/pF, n = 21; compare scale bars in Figure 3B ). Voltage dependence of activation of hPSC-derived nociceptors was more hyperpolarized than that of rat DRGs at both developmental stages ( Figure 3C ).
V half of inactivation of all nociceptors was more negative than that of TTXr currents from P6 DRGs and much closer to that of E14-E16 DRGs, suggesting that the NAV subtype expression may be similar to developing sensory neurons. Fast inactivation of TTXr currents from E14-E16 DRGs showed two components ( Figure 3D ), reflecting the expression of more than one NAV subtype, probably including NAV1.5. In heterologous expression systems, NAV1.5 shows hyperpolarized fast inactivation compared with NAV1.8 ( Figure 2E ). Nevertheless, V half of TTXr fast inactivation in human nociceptors (À93.0 ± 2.3 mV; À90,7 ± 1.6 mV for HUES6-and hiPSC-derived nociceptors, respectively) is still more hyperpolarized than that of NAV1.5 expressed in ND7/23 cells (À79.9 ± 2.4 mV). Also, the activation V half s differ. This may be due to a differential regulation of NAV1.5 in human nociceptors compared with heterologous expression systems.
NAV1.5 is less resistant to TTX than NAV1.8 (IC 50 for NAV1.5: 1-6 mM, for NAV1.8: 46 ± 10 mM; Renganathan et al., 2002) . We took advantage of these diverse resistances to isolate the NAV1.5 current component from NAV1.8 and NAV1.9. Five mM TTX blocked heterologously expressed NAV1.5 by more than 65% (67% ± 3.6%), a concentration at which NAV1.8 was only blocked by 13.1% ± 2.7% ( Figures 4A and 4B ). The unblocked current fractions for hPSC-derived nociceptors were 42.5% ± 3.5% and 43.0% ± 1.5% (hiPSC-and HUES6-derived nociceptors, respectively), very similar to our results for NAV1.5 in heterologous expression systems (33% ± 3.6%; Figures  4B and 4C ). These results confirm that our hPSC-derived nociceptors express a substantial level of functional NAV1.5. NAV1.8 is supposed to support higher-frequency firing (Blair and Bean, 2002) , especially due to its more depolarized fast-inactivation properties. TTXr fast inactivation is enhanced in the human nociceptors investigated here, suggesting that the firing rate may be reduced compared with mature healthy neurons. It is possible that this prevents nociceptive malfunction during development and supports normal development. Mutations in NAVs may interfere with this regulation and cause pain syndromes, such as PEPD, having its onset sometimes already in utero (Lampert et al., 2014) . The model presented here offers a platform to investigate NAV physiology, and patient-derived nociceptors may be a useful tool to elucidate NAV dysfunction.
In summary, we successfully differentiated human sensory neurons from hPSCs. Our cells express canonical markers of nociceptors and exhibit many of their characteristic electrophysiological properties. hPSC-derived nociceptors have the potential to serve as a model system to interrogate the physiology and pharmacology of human TTXr NAVs, which emerged as prime targets for the development of new pain treatment.
We find that TTXr currents of these nociceptors are more similar to those of NAV1.5 than to those of NAV1.8 and NAV1.9, and the electrophysiological and pharmacological properties of NAV1.5, especially of fast inactivation, fit well to that of embryonic rodent DRGs. These data reveal that (D and E) Voltage dependencies of activation (D) and steady-state fast inactivation (E) of HUES6-derived nociceptors (triangles, n = 15 cells of one experiment), hiPSC-derived nociceptors (diamonds, n = 23-26 cells), NAV1.8 (circles, n = 10-13 cells of one experiment), and NAV1.5 (squares, n = 8-10 cells of one experiment) and, shown only in (E), co-expression of NAV1.8 and NAV1.5 (triangles, n = 8 cells of one experiment). All error bars indicate the SEM.
hPSC-derived nociceptors offer a unique opportunity of modeling developing nociceptors and may mimic in particular early-onset pain syndromes.
The differentiation of hiPSCs gained from patients with pain syndromes using this chemical approach might be a promising tool for the investigation of the 
EXPERIMENTAL PROCEDURES
Generation of Nociceptors from hiPSCs and hESCs
Following Institutional Review Board approval (Nr. 4120: ''Generierung von humanen neuronalen Modellen bei neurodegenerativen Erkrankungen'') and informed consent at the outpatient movement disorder clinic at the Department of Molecular Neurology, Universitätsklinikum Erlangen, Germany, hiPSCs were derived from a healthy Caucasian individual (previously referred to as Ctrl-1, Havlicek et al., 2014) with no history of neurologic disease. Fibroblasts isolated from dermal punch biopsies were reprogrammed by retroviral transduction with SOX2, KLF4 and c-MYC, and OCT3/4 (Takahashi et al., 2007) and were tested for pluripotency as described previously (Havlicek et al., 2014) . All experiments with hESCs (HUES6) were carried out in accordance with the German Stem Cell Act (RKI AZ. 3.04.02/0069). hPSCs were cultured on Matrigel (BD Biosciences) in mTeSR1 medium (Stem Cell Technologies) and passaged in clumps.
Nociceptor differentiation was performed with modifications to Chambers et al. (2012) . In brief, hPSCs were seeded as single cells at a density of 85,000-100,000 cells/cm 2 in presence of Y-27632 (Sigma-Aldrich). When cells reached 90%-100% confluence, dual SMAD inhibition was initiated by 100 nM LDN-193189 and 10 mM SB431542 on days 1-5. Cells were fed daily, and N2/B27 medium (N2/B27 medium: DMEM/F12/Glutamax, with N2 and B27 [without VitA]; all LifeTechnologies) was added in increasing 25% increments every other day starting on day 4. Three mM CHIR99021, 10 mM SU5402, and 10 mM DAPT were added on days 2-10. On day 10, cells were dissociated using TrypLE Express (LifeTechnologies) and seeded on glass coverslips precoated with polyornithine/laminin (LifeTechnologies) or poly-D-lysine (Sigma-Aldrich). Longterm neuronal culture medium consisted of N2/B27 medium containing adjusted growth factor concentrations of 20 ng/ml human-b-NGF (beta nerve growth factor; R&D Systems), BDNF (brain derived neurotrophic factor), GDNF (glial-cell-line-derived neurotrophic factor; both Peprotech), and addition of 200 ng/ml ascorbic acid (Sigma-Aldrich).
Animals and DRG Culture
All animal experiments were performed in accordance with ethical guidelines established by German animal protection law approved by the animal protection committee of Regierung Mittelfranken, Germany. Embryos were removed from Wistar rats sacrificed at days 14-16 of pregnancy. DRGs were isolated from the embryos or the P6 rats and pooled into groups for RNA extraction and cell preparation (as described in Klinger et al., 2012) . Cells were loaded on poly-D-lysine-coated glass coverslips, and experiments were performed the following day.
Culture of Cell Lines and Transfection of ND7/23 Cells
ND7/23 cells were maintained in DMEM (LifeTechnologies), including 10% fetal bovine serum (FBS), 4.5 g/L glucose, and 1% penicillin/streptomycin (PAA Laboratories) and transfected with human NAV1.5-cDNA, NAV1.8-cDNA, or both and GFP, using Nanofectin transfection reagent (PAA Laboratories). For the stable NAV1.5-HEK293 cell line, 30 g/ml Zeocin (Biochrom) was added, and glucose was reduced to 1 g/L. 
qRT-PCR
RNA from DRGs and hPSC-derived nociceptors cultures was extracted and reversely transcribed, and PCRs were performed as previously described, using an Eppendorf realplex4 cycler (Eppendorf; Havlicek et al., 2014) and exon-spanning primers shown in Table S2 . Differences in expression levels were determined by the DCq method.
Immunofluorescence Stainings
Immunofluorescence stainings were performed as described previously (Havlicek et al., 2014) 
Patch-Clamp Experiments of hPSC-Derived Nociceptors and DRG Cultures
Whole-cell recordings were performed with a HEKA EPC-10USB amplifier (HEKA electronics) using the following bath solution for voltage clamp: 140 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, 20 mM TEA-Cl, 1 mM 4-Aminopyridin, 0.1 mM CdCl 2 , and 10 mM D-glucose (pH 7.4). Glass electrodes (2.0-3.5 MU) were filled with solution containing 10 mM NaCl, 140 mM CsF, 10 mM HEPES, 1 mM EGTA, 5 mM D-glucose, and 5 mM TEA-Cl (pH 7.3). For voltage clamp recordings of DRGs, extracellular Na + was reduced (40 mM NaCl, 75 mM Cholin-Cl), and the internal solution contained 10 mM NaCl, 140 mM CsF, 10 mM HEPES, 1 mM EGTA, 15 mM D-glucose, and 10 mM TEA-Cl (pH 7.3).
For current clamp experiments the external solution contained 140 mM NaCl, 3 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , and 10 mM HEPES, (pH 7.4), and internal the solution contained 4 mM NaCl, 135 mM K-gluconate, 3 mM MgCl 2 , 5 mM EGTA, 5 mM HEPES, 2 mM Na 2 -ATP, and 0.3 mM Na 3 -GTP (pH 7.25).
TTX (BIOTREND chemicals) was applied via a gravity-driven perfusion system or directly added to the bath solution prior to experiments. Capacitive transients were compensated for and leak (P/4) corrected for using the PatchMaster software (HEKA).
One hundred ms voltage pulses from a holding potential of À120 mV (for nociceptors) or À90 mV (for rat DRGs) to a range of potentials in 10 mV steps every 5 s were used to generate current-voltage (I-V) curves, which were fitted with a Boltzmann equation: G Na = G Na,max / 1 + exp [(Vm -V half ) / k], where G Na is the sodium conductance, G Na,max is the maximal sodium conductance, V half is the potential at which activation is half maximal, and k is the slope factor.
Voltage dependence of steady-state fast inactivation was assessed by 500 ms steps to various potentials in 10 mV increments followed by a test pulse to 20 mV to assess available channels.
Patch-Clamp Experiments on Cell Lines and Transfected Cells
Cell lines transiently expressing human NAV1.5, NAV1.8, or a combination of both were patch-clamped using an EPC-10USB or an Axopatch 200B amplifier and pClamp software (Axon Instruments). Holding potential was À120 mV. The external solution contained 140 mM NaCl, 3 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 10-20 mM D-glucose (pH 7.4). Internal solution contained 140 mM CsF, 10 mM NaCl, 10 mM HEPES, 1 mM EGTA, and 15 mM D-glucose (pH 7.38). External NaCl was reduced for recordings of the stable NAV1.5-HEK293 cell line: 70 mM NaCl, 70 mM Cholin-Cl, 3 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 10 mM HEPES, and 20 mM D-glucose (pH 7.4). Internal NaCl was reduced to 2 mM, and TEA-Cl 10 mM was added to the pipette solution to improve recording conditions for NAV1.8 in ND7/23 cells.
For TTXr-current isolation, the bath solutions were supplemented with 500 nM TTX (control) or 5 mM TTX and continuously superfused during repetitive pulses to 20 mV every 5 s. Currents were normalized to the mean of the first four test pulses.
All patch-clamp recordings were performed at room temperature.
Statistics
Statistical analyses were performed in GraphPad Prism version 5.00 or Origin 8.6. Two groups were compared with one-tailed or two-tailed t tests. Kruskal-Wallis/One-Way ANOVA followed by Dunn's or Tukey multiple comparison tests were used when three or more groups were compared. p values < 0.05 were considered significant and are indicated as follows: * p < 0.05, ** p < 0.01, and ****p < 0.0001. All data are shown as mean ± SEM unless otherwise stated.
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